Oramed Reaches 25% Enrollment in Its Second of Two Concurrent Phase 3 Oral Insulin Trials

– ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol currently underway – ORA-D-013-1, the larger and first of the 2-part trial to commence, nears 65% enrollment NEW YORK, Aug. 24, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug […]